Akebia Therapeutics
As of the edition of 20 October 2026, Akebia Therapeutics runs 7 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Keryx Biopharmaceuticals: acquired in 2018; successor Akebia Therapeutics
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 3 |
| Went quiet | 1 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Vadadustat | Ends 2034 (patent) | 4 |
| Ferric citrate anhydrous | none listed | 0 |
| Sulodexide | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Akebia Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Pregnancy and women's health: 24 trials led
- Urinary and reproductive: 24 trials led
- Blood and lymph: 19 trials led